Moreover, we observed that empagliflozin exerted regulatory effects on inflammatory cytokines and fibrosis-related genes comparable to those of the GLP-1 receptor agonist semaglutide, which aligns with previous reports highlighting the hepatoprotective actions of GLP-1RAs in NAFLD [39]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.